38 related articles for article (PubMed ID: 38553867)
1. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
Zhao D; Long X; Wang J
Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
[TBL] [Abstract][Full Text] [Related]
2. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
3. Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS.
Dai M; Dou X; Chen M; Yang J; Long J; Lin Y
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4105-4121. PubMed ID: 38032491
[TBL] [Abstract][Full Text] [Related]
4. Safety assessment of clomiphene: a real-world pharmacovigilance analysis from the Food and Drug Administration adverse event reporting system.
Shao Y; Ma L; Zhou J; Yang B
Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38771884
[TBL] [Abstract][Full Text] [Related]
5. Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study.
Oka Y; Matsumoto J; Takeda T; Iwata N; Niimura T; Ozaki AF; Bekku K; Hamano H; Araki M; Ishizawa K; Zamami Y; Ariyoshi N
Int J Clin Pharm; 2024 Jun; 46(3):745-750. PubMed ID: 38632203
[TBL] [Abstract][Full Text] [Related]
6. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
Zhao D; Zhang W; Liu Y; Yan Z
Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
8. A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.
Yan Y; Wang L; Yuan Y; Xu J; Chen Y; Wu B
Expert Opin Drug Saf; 2024 Jun; 23(6):771-776. PubMed ID: 37615268
[TBL] [Abstract][Full Text] [Related]
9. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.
Cecco S; Puligheddu S; Fusaroli M; Gerratana L; Yan M; Zamagni C; De Ponti F; Raschi E
Target Oncol; 2024 May; 19(3):435-445. PubMed ID: 38696126
[TBL] [Abstract][Full Text] [Related]
10. Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system.
Li Z; Zou W; Yuan J; Zhong Y; Fu Z
Expert Opin Drug Saf; 2024 Jun; 23(6):763-770. PubMed ID: 37515501
[TBL] [Abstract][Full Text] [Related]
11. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
[TBL] [Abstract][Full Text] [Related]
12. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.
Muhammed A; Thomas C; Kalaiselvan V; Undela K
Expert Opin Drug Saf; 2024 Jun; 23(6):731-742. PubMed ID: 37986140
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic-associated vanishing bile duct syndrome: a real-world retrospective and pharmacovigilance database analysis.
Wang J; Wang S; Wu C; Deng Z
Infection; 2024 Jun; 52(3):891-899. PubMed ID: 37996645
[TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
15. Assessing the safety of bedaquiline: insight from adverse event reporting system analysis.
Wu J; Pan H; Shen L; Zhao M
Front Pharmacol; 2024; 15():1382441. PubMed ID: 38783951
[TBL] [Abstract][Full Text] [Related]
16. Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis.
Dai MF; Wang X; Xin WX; Kong SS; Xu WB; Ding HY; Fang L
Expert Rev Anticancer Ther; 2024 May; ():1-10. PubMed ID: 38761169
[TBL] [Abstract][Full Text] [Related]
17. Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis.
Zhao Y; Li Z; Zhang K; Wang N
Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38769926
[TBL] [Abstract][Full Text] [Related]
18. Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database.
Liu Y; Yang R; Feng H; Du Y; Yang B; Zhang M; He P; Ma B; Niu F
Sci Rep; 2024 May; 14(1):12231. PubMed ID: 38806549
[TBL] [Abstract][Full Text] [Related]
19. Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database.
Chen J; Xu S; Yu W; Sun C; Zhang W
Front Pharmacol; 2024; 15():1255918. PubMed ID: 38584605
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database.
Li D; Zhang Y; Ni JQ; Zhu J; Lu WT; Chen YL; Cheng L; Wang YQ; Li QJ; Wang J; Lu YB; Chen J; Chen L
Front Pharmacol; 2024; 15():1372401. PubMed ID: 38803441
[No Abstract] [Full Text] [Related]
[Next] [New Search]
